¼¼°èÀÇ ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ½ÃÀå
Digital Twin in Healthcare
»óǰÄÚµå : 1744706
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,130,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,390,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ¼¼°è ½ÃÀåÀº 2030³â±îÁö 27¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 7¾ï 6,660¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 23.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ µðÁöÅÐ Æ®À© ¼ÒÇÁÆ®¿þ¾î´Â CAGR 20.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µðÁöÅÐ Æ®À© ¼­ºñ½º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 27.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 880¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 30.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ½ÃÀåÀº 2024³â¿¡ 2¾ï 880¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 30.7%·Î 2030³â±îÁö 6¾ï 4,290¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 19.2%¿Í 20.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 19.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µðÁöÅÐ Æ®À©ÀÌ Àü ¼¼°è ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

µðÁöÅÐ Æ®À© ±â¼úÀº ȯÀÚ, ÀÇ·á±â±â, ÀÇ·á ÇÁ·Î¼¼½ºÀÇ ½Ç½Ã°£ µ¿Àû °¡»ó º¹Á¦º»À» »ý¼ºÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» Á¦°øÇÔÀ¸·Î½á ÇコÄÉ¾î ºÐ¾ßÀÇ Çõ½ÅÀ¸·Î ±ÞºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ º¹Á¦º»Àº ÀüÀڰǰ­±â·Ï(EHR), ¿þ¾î·¯ºí ¼¾¼­, ¿µ»ó ½Ã½ºÅÛ, À¯ÀüüÇÐ µîÀÇ µ¥ÀÌÅÍ·Î ±¸ÃàµÇ¸ç, °¡»ó ȯ°æ¿¡¼­ ½ÇÁ¦ ½Ã³ª¸®¿À¸¦ ½Ã¹Ä·¹À̼ÇÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ÀÌ È¹±âÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ÀÓ»óÀǴ ȯÀÚ¿¡°Ô À§ÇèÀ» ÃÊ·¡ÇÏÁö ¾ÊÀ¸¸é¼­µµ Àü·Ê ¾ø´Â Á¤È®µµ·Î °³ÀÔÀ» Å×½ºÆ®Çϰí, Áúº´ÀÇ ÁøÇàÀ» ¿¹ÃøÇϰí, Ä¡·á¸¦ ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ Æ®À©Àº ȯÀÚÀÇ »ý¹°ÇÐÀû ±â´ÉÀ» ÀçÇöÇÔÀ¸·Î½á °¡»ó ½ÇÇè´ë ¿ªÇÒÀ» Çϸç, ÀÇ»ç´Â ȯÀÚ°¡ ´Ù¾çÇÑ ¾à¹° Ä¡·á, ¼ö¼ú, »ýȰ½À°ü °³¼±¿¡ ¾î¶»°Ô ¹ÝÀÀÇÏ´ÂÁö Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. º´¿øµµ µðÁöÅÐ Æ®À©À» µµÀÔÇØ ½Ã¼³ ¿î¿µ ÃÖÀûÈ­, Àåºñ °íÀå ¿¹Ãø, ȯÀÚ µ¿¼± °£¼ÒÈ­ µîÀ» ÅëÇØ È¿À²¼º°ú ´ë±â ½Ã°£ ´ÜÃàÀ» ²ÒÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Æ®À©ÀÇ °¡´É¼ºÀº ¸¸¼ºÁúȯ °ü¸®¿¡µµ Àû¿ëµÇ¸ç, Áö¼ÓÀûÀÎ µ¥ÀÌÅÍ Çǵ带 ÅëÇØ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú °³Àκ° ¸ÂÃã Ä¡·á°¡ °¡´ÉÇØÁý´Ï´Ù. °í·ÉÈ­, ¸¸¼ºÁúȯÀÇ Áõ°¡, ÇÑÁ¤µÈ ÀÚ¿ø µî ÀÇ·á½Ã½ºÅÛÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ´Â °¡¿îµ¥, µðÁöÅÐ Æ®À©Àº »çÀü ¿¹¹æÀûÀÌ°í ¿¹Ãø °¡´ÉÇϸç È¿À²ÀûÀÎ ÀǷḦ À§ÇÑ ±æÀ» Á¦½ÃÇÕ´Ï´Ù. µðÁöÅÐ Æ®À©ÀÇ ÅëÇÕÀº ¼öµ¿Àû Ä¡·á¿¡¼­ ¿¹¹æÀû, µ¥ÀÌÅÍ ±â¹Ý ÀÇ·á ¼­ºñ½º·ÎÀÇ ±Ùº»ÀûÀÎ ÀüȯÀ» ÀǹÌÇÕ´Ï´Ù.

±â¼úÀÌ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µðÁöÅÐ Æ®À©ÀÇ °³¹ß°ú º¸±ÞÀ» ¾î¶»°Ô ÃËÁøÇϰí Àִ°¡?

ÀΰøÁö´É(AI), ¸Ó½Å·¯´×(ML), ºòµ¥ÀÌÅÍ ºÐ¼®, »ç¹°ÀÎÅͳÝ(IoT) µî ÷´Ü ±â¼úÀÇ ÅëÇÕÀº ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µðÁöÅÐ Æ®À© ¼Ö·ç¼ÇÀÇ °³¹ß°ú äÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ½Ã½ºÅÛ µ¿ÀÛÀÇ Á¤È®ÇÑ ¿¹Ãø ¸ðµ¨À» ±¸ÃàÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, µö·¯´× ±â¼úÀº À̹ÌÁö µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí ÀÓ»ó °á°ú¿Í »ó°ü°ü°è¸¦ ºÐ¼®ÇÏ´Â µ¥ »ç¿ëµÇ¾î µðÁöÅÐ Æ®À©ÀÌ Áø´Ü Á¤È®µµ ¹× ¼ö¼ú °èȹÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ½º¸¶Æ® ¿öÄ¡¿¡¼­ ÀÓÇöõÆ® ¸ð´ÏÅÍ¿¡ À̸£±â±îÁö IoT Áö¿ø ÀÇ·á±â±âÀÇ ±¤¹üÀ§ÇÑ º¸±ÞÀº ȯÀÚÀÇ µðÁöÅÐ Æ®À©À» Áö¼ÓÀûÀ¸·Î ¾÷µ¥ÀÌÆ®ÇÏ´Â ½Ç½Ã°£ »ý¸®Àû µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© »ì¾Æ¼­ ÁøÈ­ÇÏ´Â ¸ðµ¨À» »ý¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ°ú ¿§Áö ¾Ö³Î¸®Æ½½º´Â ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ ³ôÀº ÄÄÇ»ÆÃ ¼ö¿ä¸¦ Áö¿øÇϱâ À§ÇØ ÀÌÁ¾ ¼Ò½º·ÎºÎÅÍÀÇ µ¥ÀÌÅÍ ÅëÇÕ°ú È¿À²ÀûÀΠ󸮸¦ º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ HL7 FHIR°ú °°Àº »óÈ£¿î¿ë¼º Ç¥ÁØÀº °ú°Å µ¥ÀÌÅÍÀÇ »çÀÏ·ÎÈ­¸¦ ±Øº¹Çϰí ÀüÀÚ ÀÇ·á ±â·Ï ¹× ±âŸ ÀÓ»ó µ¥ÀÌÅͺ£À̽º¸¦ µðÁöÅÐ Æ®À© ¿¡ÄڽýºÅÛ¿¡ ½±°Ô ÅëÇÕÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. µðÁöÅÐ Æ®À©À» 3D·Î ½Ã°¢È­ÇÏ¿© ¼ö¼ú ¸®Çã¼³, ÇØºÎÇÐ ±³À°, ¿ø°ÝÁø·á¿¡ Ȱ¿ëÇϱâ À§ÇØ °¡»óÇö½Ç°ú Áõ°­Çö½Ç(AR)µµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÇÇö ±â¼úÀÌ ¼º¼÷ÇØÁü¿¡ µû¶ó µðÁöÅÐ Æ®À© Ç÷§ÆûÀ» ´ëÇк´¿ø¿¡¼­ ¿Ü·¡ Áø·á¼Ò±îÁö ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Â ½ÇÇö °¡´É¼º°ú °¡°ÝÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

°³ÀθÂÃãÀÇ·á¿Í ¿¹¹æÀÇ·á¿¡¼­ µðÁöÅÐ Æ®À© ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µðÁöÅÐ Æ®À© ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¸ÂÃãÇü ÀÇ·á, ¿¹¹æ ÀÇ·á, °¡Ä¡ ±â¹Ý °á°ú·ÎÀÇ »ê¾÷ º¯È­¿Í ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÇ¾î ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ È¹ÀÏÀûÀÎ Ä¡·á ¸ðµ¨·Î´Â À¯Àü, »ýȰ½À°ü, µ¿¹ÝÁúȯ µî °³ÀÎÂ÷¸¦ °í·ÁÇÏÁö ¸øÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. µðÁöÅÐ Æ®À©Àº °³ÀÎÀÇ °íÀ¯ÇÑ »ý¸®Àû ÇÁ·ÎÇÊÀ» °¡»óÀ¸·Î Ç¥ÇöÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇϰí, ÀÓ»óÀǰ¡ °³ÀÔ¿¡ ´ëÇÑ ¹ÝÀÀÀ» ½Ã¹Ä·¹À̼ÇÇÏ°í ±×¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¿¹¸¦ µé¾î, Á¾¾çÇп¡¼­´Â µðÁöÅÐ Æ®À©À» ÅëÇØ Á¾¾çÀÇ ¼ºÀåÀ» ¸ðµ¨¸µÇÏ°í Æ¯Á¤ ȯÀÚ°¡ ´Ù¾çÇÑ È­Çпä¹ý¿¡ ¾î¶»°Ô ¹ÝÀÀÇÒÁö¸¦ ¿¹ÃøÇÏ¿© ºÒÇÊ¿äÇÑ µ¶¼ºÀ» ÇÇÇϰí Ä¡·á È¿°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ½ÉÀåÇп¡¼­´Â ºÎÁ¤¸ÆÀÇ À§ÇèÀ» Æò°¡Çϰųª ½É¹ÚÁ¶À²±â ¼³Á¤À» ÃÖÀûÈ­Çϱâ À§ÇØ ½ÇÁ¦ »ç¿ë Àü¿¡ °¡»ó ½ÉÀå ¸ðµ¨À» »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ Æ®À©Àº ´ë»ç ÁõÈıºÀÇ Á¶±â °æ°í ½ÅÈ£¸¦ º¸¿©ÁÖ°í, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ °¨ÁöÇϰí, Áõ»óÀÌ ³ªÅ¸³ª±â Àü¿¡ ÀáÀçÀûÀÎ ¾à¹° »óÈ£ÀÛ¿ëÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¹¹æÀû Á¢±Ù ¹æ½ÄÀº °Ç°­ °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀÔ¿øÀ²°ú Àüü ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ ½º½º·Î°¡ µðÁöÅÐ µµ±¸¸¦ »ç¿ëÇÏ¿© ÀÚ½ÅÀÇ °Ç°­À» °ü¸®Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¸ç, µðÁöÅÐ Æ®À©Àº °³ÀÎÀÌ ÀÚ½ÅÀÇ °Ç°­ »óŸ¦ ½Ã°¢È­Çϰí ÀÌÇØÇÒ ¼ö ÀÖ´Â Æ÷°ýÀûÀÌ°í °³ÀÎÈ­µÈ ·»Á Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿äÀÇ Áõ°¡´Â ÇコÄÉ¾î ½Ã½ºÅÛÀÌ Á¤¹ÐÀÇ·áÀÇ ±â¹Ý µµ±¸·Î¼­ µðÁöÅÐ Æ®À© Ç÷§Æû¿¡ ÅõÀÚÇÒ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µðÁöÅÐ Æ®À© ±â¼úÀÇ ¼¼°è ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀϱî?

ÇコÄÉ¾î ºÐ¾ß µðÁöÅÐ Æ®À© ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ȯÀÚ Áß½É Ä¡·á ¸ðµ¨, ÀÇ·áºñ Áõ°¡, Àü·«Àû ¹Î°ü ÆÄÆ®³Ê½ÊÀÇ °áÇÕ¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â ºñ¿ë »ó½Â, ÀÓ»óÀÇ»ç ºÎÁ·, ȯÀÚ º¹À⼺ Áõ°¡¿¡ Á÷¸éÇÏ¿© ÀÇ·á ½Ã½ºÅÛÀÌ º¸´Ù È¿À²ÀûÀÌ°í ¿¹Ãø °¡´ÉÇÑ ÀÇ·á ½Ã½ºÅÛÀ» ÇÊ¿ä·Î ÇÑ´Ù´Â Á¡ÀÔ´Ï´Ù. µðÁöÅÐ Æ®À©À» ÅëÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â °á°ú¸¦ ½Ã¹Ä·¹À̼ÇÇϰí, Ä¡·á °æ·Î¸¦ ÃÖÀûÈ­Çϰí, Ä¡·á ¼±Åÿ¡ ´ëÇÑ ½ÃÇàÂø¿À¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿øµ¿·ÂÀº ¿þ¾î·¯ºí ±â¼ú, À¯ÀüüÇÐ, µðÁöÅÐ °Ç°­ ¾Û¿¡ ÀÇÇØ ÃËÁøµÇ´Â °Ç°­ µ¥ÀÌÅÍÀÇ Æø¹ßÀûÀÎ Áõ°¡À̸ç, ÀÌ´Â °íµµ·Î °³ÀÎÈ­µÈ µðÁöÅÐ ¸ðµ¨¿¡ ÇÊ¿äÇÑ ¿øÀڷḦ Á¦°øÇÕ´Ï´Ù. ºÏ¹Ì¿Í À¯·´ µîÀÇ Áö¿ª¿¡¼­´Â ±ÔÁ¦ ±â°ü°ú Á¤ºÎµµ µðÁöÅÐ Çコ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, AI ±â¹Ý ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ µµÀÔÀ» Àå·ÁÇÏ´Â º¸Á¶±Ý°ú ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¼ú ¹× ÇコÄÉ¾î ±â¾÷ÀÇ ÅõÀÚ´Â µðÁöÅÐ Æ®À© Ç÷§ÆûÀÇ ¿¬±¸ °³¹ßÀ» °¡¼ÓÈ­Çϰí, Çмú ¿¬±¸ ±â°üÀº ÀÌ·¯ÇÑ µµ±¸¿¡ ´ëÇÑ ÀÓ»ó °ËÁõÀ» ¹ßÇ¥ÇÏ¿© ÀÌÇØ°ü°èÀÚ °£ÀÇ ½Å·Ú¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 »çÅ·ΠÀÎÇØ ¿ø°ÝÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ëÀÌ È®´ëµÇ¸é¼­ ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ´ëÇÑ º¸´Ù ÅëÇÕÀûÀÌ°í µ¥ÀÌÅÍ Áß½ÉÀûÀÎ Á¢±Ù ¹æ½ÄÀ» À§ÇÑ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀ» Á¾ÇÕÇϸé, µðÁöÅÐ Æ®À© ±â¼úÀº º¸´Ù ½º¸¶Æ®ÇÏ°í ¾ÈÀüÇϸç Áö¼Ó°¡´ÉÇÑ ÀÇ·á ½Ã½ºÅÛÀ¸·ÎÀÇ Àüȯ¿¡ ÀÖ¾î Àü ¼¼°èÀûÀ¸·Î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º), ¿ëµµ(Drug Discovery & Development, ¸ÂÃãÇü ÀÇ·á, ¼ö¼ú °èȹ¡¤ÀÇ·á ±³À°, ÀÇ·á±â±â ¼³°è¡¤°Ë»ç, ÇコÄÉ¾î ¿öÅ©Ç÷οì ÃÖÀûÈ­¡¤ÀÚ»ê °ü¸®, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿À Á¦¾à ±â¾÷, ¿¬±¸°³¹ß, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 42°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Twin in Healthcare Market to Reach US$2.7 Billion by 2030

The global market for Digital Twin in Healthcare estimated at US$766.6 Million in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 23.5% over the analysis period 2024-2030. Digital Twin Software, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Digital Twin Services segment is estimated at 27.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$208.8 Million While China is Forecast to Grow at 30.7% CAGR

The Digital Twin in Healthcare market in the U.S. is estimated at US$208.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$642.9 Million by the year 2030 trailing a CAGR of 30.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.2% and 20.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.7% CAGR.

Global Digital Twin in Healthcare Market - Key Trends & Drivers Summarized

Why Are Digital Twins Poised to Revolutionize Healthcare Systems Globally?

Digital twin technology is rapidly emerging as a transformative force in healthcare, offering the ability to create real-time, dynamic virtual replicas of patients, medical devices, or healthcare processes. These digital counterparts are built using data from electronic health records (EHRs), wearable sensors, imaging systems, and genomics to simulate and analyze real-world scenarios in a virtual environment. This revolutionary approach enables clinicians to test interventions, predict disease progression, and customize treatments with unprecedented precision-without exposing patients to risk. By replicating a patient’s biological functions, a digital twin can act as a virtual test bed, allowing doctors to assess how that individual might respond to various medications, surgical procedures, or lifestyle modifications. Hospitals are also deploying digital twins to optimize facility operations, predict equipment failures, and streamline patient flow, thereby enhancing efficiency and reducing wait times. The potential of digital twins extends to chronic disease management, where continuous data feeds enable real-time monitoring and personalized care. As healthcare systems face increasing strain from aging populations, rising chronic disease burdens, and limited resources, digital twins offer a pathway to proactive, predictive, and highly efficient medical care. Their integration represents a fundamental shift from reactive treatment to preventive, data-driven healthcare delivery.

How Is Technology Driving the Development and Adoption of Digital Twins in Healthcare?

The integration of advanced technologies such as artificial intelligence (AI), machine learning (ML), big data analytics, and the Internet of Things (IoT) is accelerating the development and adoption of digital twin solutions in healthcare. AI and ML algorithms play a crucial role in interpreting vast datasets to build accurate, predictive models of patient physiology or system behavior. For example, deep learning techniques are used to analyze imaging data and correlate it with clinical outcomes, helping digital twins refine diagnostic accuracy or surgical planning. The widespread deployment of IoT-enabled medical devices-ranging from smartwatches to implantable monitors-provides real-time physiological data that continuously updates a patient’s digital twin, creating a living, evolving model. Cloud computing and edge analytics ensure that data from disparate sources is aggregated and processed efficiently, supporting the high computational demands of these systems. Moreover, interoperability standards such as HL7 FHIR are helping overcome historical data silos, making it easier to integrate electronic health records and other clinical databases into digital twin ecosystems. Virtual and augmented reality are also being explored to visualize digital twins in 3D, aiding in surgical rehearsal, anatomical education, and remote consultations. As these enabling technologies mature, they are expanding the feasibility and affordability of deploying digital twin platforms across diverse healthcare settings, from academic medical centers to outpatient clinics.

Why Is There a Growing Demand for Digital Twin Technology in Personalized and Preventive Healthcare?

The growing demand for digital twin technology in healthcare is closely tied to the industry’s shift toward personalized medicine, preventive care, and value-based outcomes. Traditional one-size-fits-all treatment models often fall short in accounting for individual variability in genetics, lifestyle, and comorbidities. Digital twins address this gap by creating a virtual representation of an individual’s unique physiological profile, enabling clinicians to simulate responses to interventions and tailor treatments accordingly. In oncology, for example, digital twins can model tumor growth and predict how a specific patient might respond to various chemotherapy regimens, thereby avoiding unnecessary toxicity and improving therapeutic efficacy. In cardiology, virtual heart models can be used to assess arrhythmia risks or optimize pacemaker settings before actual implementation. Preventive applications are also expanding: digital twins can flag early warning signs of metabolic syndrome, detect subtle shifts in biomarker trends, or identify potential medication interactions before symptoms occur. This proactive approach not only improves health outcomes but also reduces hospitalization rates and overall healthcare costs. Furthermore, patients themselves are increasingly engaged in managing their health through digital tools, and digital twins provide a comprehensive, personalized lens through which individuals can visualize and understand their health trajectories. This growing demand is reinforcing the case for healthcare systems to invest in digital twin platforms as foundational tools for precision medicine.

What Are the Key Drivers Fueling the Global Growth of Digital Twin Technology in Healthcare?

The growth in the digital twin in healthcare market is being driven by a confluence of technological advancement, patient-centric care models, rising healthcare expenditures, and strategic public-private partnerships. One of the most significant drivers is the need for healthcare systems to become more efficient and predictive in the face of rising costs, clinician shortages, and increasing patient complexity. Digital twins enable providers to simulate outcomes, optimize care pathways, and reduce trial-and-error in treatment selection-all of which support better clinical and financial performance. Another key driver is the explosion of health data, facilitated by wearable tech, genomics, and digital health apps, which provides the raw material needed to power highly personalized digital models. Regulatory bodies and governments in regions such as North America and Europe are also promoting digital health innovation, offering grants and frameworks that encourage the adoption of AI-powered healthcare solutions. Investment from major technology and healthcare companies is accelerating R&D in digital twin platforms, while academic research institutions are publishing clinical validations of these tools, building trust among stakeholders. Additionally, the increasing acceptance of telehealth and remote monitoring-fueled by the COVID-19 pandemic-has paved the way for more integrated, data-centric approaches to healthcare delivery. Collectively, these factors are positioning digital twin technology as a central pillar in the transformation toward smarter, safer, and more sustainable healthcare systems worldwide.

SCOPE OF STUDY:

The report analyzes the Digital Twin in Healthcare market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software, Services); Application (Drug Discovery & Development, Personalized Medicine, Surgical Planning & Medical Education, Medical Device Design & Testing, Healthcare Workflow Optimization & Asset Management, Other Applications); End-Use (Pharma & Bio-Pharma Companies, Research & Academia, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â